ZUG, Switzerland, June 17 /PRNewswire-FirstCall/ -- Biogen Idec (Nasdaq:
BIIB) today announced that the Therapeutic Goods Administration has approved
AMEVIVE(R) (alefacept) for sale in Australia. AMEVIVE will be marketed for
treatment of adult patients with moderate-to-severe chronic plaque psoriasis
who are candidates for phototherapy or systemic therapy.
AMEVIVE, approved in the United States last year, was the first biologic
therapy approved for the treatment of moderate-to-severe chronic plaque
psoriasis in adults.
Biogen Idec creates new standards of care in oncology and immunology. As
a global leader in the development, manufacturing and commercialization of
novel therapies, Biogen Idec transforms scientific discoveries into advances
in human healthcare. For press releases and additional information about the
company, please visit http://www.biogenidec.com.
Media Contact:
Jose Juves
Associate Director, Public Affairs
Biogen Idec
(617) 914-6524
Investment Community Contact:
Christina Dillon
Senior Manager, Investor Relations
Biogen Idec
(617) 679-2812
SOURCE Biogen Idec
 back to top
Related links:
http://www.biogenidec.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
CONTACT:
Jose Juves, Associate Director, Public
Affairs, +1-617-914- 6524, or Christina Dillon, Senior Manager,
Investor Relations, +1-617-679-2812 both of Biogen Idec
|
